Clinical Trial

Covid-19 Vaccine Immune Response in Multiple Sclerosis

Study acronym: CoVaR-MS
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Coronavirus (Covid-19) has affected millions of people worldwide. Vaccines to prevent Covid-19 infection have been offered to reduce the risk of infection. While these vaccines have been offered to people with multiple sclerosis (MS), they have not been tested in these individuals. It is uncertain whether people with MS will develop protective antibodies after a Covid-19 vaccination and how long these antibodies will last. The investigators are planning to study the immune response to the full course of Covid-19 vaccine in people with MS (study group) and compare this to people without MS or immune suppression (control group).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-03-07; most recent amendment 2025-02-03.
Status change: Recruiting → Active, Not Recruiting 2023-07-21
Trial Details
NCT Number NCT05269888
Lead Sponsor University Hospitals of North Midlands NHS Trust
Conditions Multiple Sclerosis
Enrollment 240 participants
Start Date 2022-02-16
Primary Completion 2024-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-04